Is PZRXQ or MRK a better dividend investment in 2026?

PZRXQ currently yields 2000000.00% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: PZRXQ offers higher current income.

What is the dividend yield difference between PZRXQ and MRK?

PZRXQ has a forward dividend yield of 2000000.00% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 1999997.24 percentage points.

Home › Compare › PZRXQ vs MRK

PZRXQ vs MRK: Dividend Comparison 2026

PZRXQ yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PZRXQ wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PZRXQ

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full PZRXQ calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — PZRXQ vs MRK

📍 PZRXQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PZRXQ	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PZRXQ + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PZRXQ pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PZRXQ

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, PZRXQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PZRXQ + MRK for your $10,000?

PZRXQ: 50%MRK: 50%

100% MRK50/50100% PZRXQ

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PZRXQ

No analyst data

Altman Z

-25.0

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PZRXQ buys

MRK buys

No recent congressional trades found for PZRXQ or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPZRXQMRK

Forward yield	2000000.00% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.879226400974806e+39M	$56.8K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$4.879195005460081e+39M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: PZRXQ vs MRK ($10,000, DRIP)

Year	PZRXQ Portfolio	PZRXQ Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,206	$366.19	+$200.00M → PZRXQ
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,650	$502.35	+$3738731.76M → PZRXQ
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$14,407	$694.19	+$65315062866.92M → PZRXQ
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$16,585	$967.82	+$1066400830062625.00M → PZRXQ
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$19,342	$1,363.89	+$16272182796453826560.00M → PZRXQ
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$22,913	$1,947.19	+$2.3205424011366188e+23M → PZRXQ
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$27,662	$2,823.89	+$3.0927990661046884e+27M → PZRXQ
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,159	$4,173.35	+$3.8524105697352695e+31M → PZRXQ
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$43,337	$6,308.80	+$4.484688260147987e+35M → PZRXQ
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$56,776	$9,798.13	+$4.879226400974806e+39M → PZRXQ

PZRXQ vs MRK: Complete Analysis 2026

PZRXQ — Stock

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Full PZRXQ Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this PZRXQ vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PZRXQ vs SCHD PZRXQ vs JEPI PZRXQ vs O PZRXQ vs KO PZRXQ vs MAIN PZRXQ vs JNJ PZRXQ vs ABBV PZRXQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.